Pancreatic cancer precursor lesions – Can immunotherapy prevent progression into pancreatic ductal adenocarcinoma?
Cancer Letters · 2025
DOI: 10.1016/j.canlet.2025.217662 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Letters, 2025. Verfasst von Thomas Enzler und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Michigan, Ann Arbor, MI, 40109, USA. Electronic address: tenzler@med.umich.edu. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Immunotherapy, Precancerous Conditions. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate of only 12.5 %. Early detection of PDAC or addressing risk factors for PDAC development are ways to improve outcomes. PDAC can arise from precursor lesions, including pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN), and less frequent, mucinous cystic neoplasm (MCN), and other rare precursor variants. High-risk precursor lesions harbor a substantial chance of evolving into PDAC. Such lesions can often be found in resected PDAC specimens adjacent to the cancer. Unfortunately, recognizing precursor lesions that need to be resected is often tricky, and resections frequently end in major surgical interventions. Thus, better ways to handle precursor lesions are desperately needed. We mapped the immune microenvironments (IMEs) of PanINs, IPMNs, and MCNs on a cellular level using multiplex immunofluorescence and computational imaging technology and compared the findings to PDACs and normal pancreatic tissues. We found distinct and potentially targetable mechanisms of immunosuppression between the two main precursor lesions, PanIN and IMPN. Immunosuppression in IPMNs seems partly mediated by programmed cell death protein 1 ligand (PD-L1) expression on antigen-presenting cells (APCs). By contrast, elevated numbers of regulatory T cells (Tregs) seem to be key players in the immunosuppression of PanINs. Thus, treating high-risk IPMNs with anti-PD-1 and high-risk PanINs with agents targeting Tregs, such as anti-lymphocyte associated protein 4 (anti-CTLA-4) antibodies, could reverse their immunosuppressive state. Reversal of immunosuppression will restore immunosurveillance and eventually prevent progression into PDAC. We also review relevant published and ongoing non-surgical treatment approaches for high-risk IPMNs and PanINs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Michigan, Ann Arbor, MI, 40109, USA. Electronic address: tenzler@med.umich.edu.
- Department of Surgery, University of Michigan, Ann Arbor, MI, 40109, USA.
Zitieren
APA
Enzler, T., & Frankel, T. L. (2025). Pancreatic cancer precursor lesions – Can immunotherapy prevent progression into pancreatic ductal adenocarcinoma?. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217662
Vancouver
Enzler T, Frankel TL. Pancreatic cancer precursor lesions – Can immunotherapy prevent progression into pancreatic ductal adenocarcinoma?. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217662
BibTeX
@article{Enzler2025,
author = {Enzler, Thomas and Frankel, Timothy L},
title = {Pancreatic cancer precursor lesions – Can immunotherapy prevent progression into pancreatic ductal adenocarcinoma?},
journal = {Cancer Letters},
year = {2025},
doi = {10.1016/j.canlet.2025.217662}
}
EUVIMED